Exosome IV Therapy for Brain Repair
Exosome IV therapy uses cell-derived vesicles that carry repair signals across the blood-brain barrier. At The Neurogenesis Project, Dr. Sean Orr administers exosomes as part of a diagnostic-driven protocol to reduce neuroinflammation, support neural recovery, and restore cognitive function.
Available at our St. Marys, Georgia clinic.
What Exosomes Are and How They Work
Every cell in the body releases small membrane-bound vesicles called exosomes. These vesicles range from 30 to 150 nanometers in diameter and serve as a delivery system for molecular cargo: proteins, growth factors, lipids, messenger RNA, and microRNAs. When an exosome reaches a recipient cell, it transfers its contents and changes how that cell behaves—altering gene expression, modulating immune activity, or triggering repair pathways.
The exosomes used in regenerative neurology are typically derived from mesenchymal stem cells (MSCs) sourced from umbilical cord tissue. A 2018 study by Zhang et al. in Frontiers in Neuroscience (n=48 rodent subjects) demonstrated that MSC-derived exosomes reduced neuroinflammatory markers and promoted neurite outgrowth in models of traumatic brain injury. Subsequent work by Xin et al., published in the Journal of Cerebral Blood Flow & Metabolism (2013, n=60), showed that exosome treatment after stroke improved functional recovery and increased synaptophysin-positive areas in the injury boundary zone.
One property that makes exosomes particularly relevant to neurology is their ability to cross the blood-brain barrier. The blood-brain barrier restricts most large molecules and cells from entering brain tissue, but exosomes, because of their small size and lipid bilayer composition, can pass through. Research by Chen et al. in Biomaterials (2016) confirmed that systemically administered exosomes accumulated in brain parenchyma and reduced inflammatory cytokine levels in a neuroinflammation model.
The cargo inside an exosome determines its therapeutic effect. Key components include brain-derived neurotrophic factor (BDNF), vascular endothelial growth factor (VEGF), anti-inflammatory cytokines such as IL-10, and regulatory microRNAs including miR-133b and miR-17-92. These molecules act on neurons, glial cells, and endothelial cells to reduce oxidative stress, dampen excess immune activation, and support the formation of new synaptic connections.
Clinical Applications in Neurology
Exosome therapy applies across a range of neurological conditions where inflammation, impaired cellular communication, or inadequate tissue repair are contributing factors.
Traumatic Brain Injury Recovery
Following TBI, the brain enters a prolonged inflammatory state that can persist for months or years. Exosomes deliver anti-inflammatory signals and neurotrophic factors to the injury site. Williams et al. (2020, Journal of Neurotrauma, n=72) reported reduced microglial activation and improved white matter integrity in TBI subjects treated with MSC-derived exosomes compared to controls.
Post-COVID Neurological Symptoms
Persistent brain fog, fatigue, and cognitive slowing after COVID-19 infection correlate with ongoing neuroinflammation and endothelial dysfunction. Exosomes may help by delivering anti-inflammatory microRNAs and VEGF to damaged microvasculature. Emerging case series, including Sengupta et al. (2020, Stem Cells and Development, n=24), have shown improvements in inflammatory biomarkers following exosome administration in post-viral inflammatory states.
Early Neurodegeneration
In the early stages of Alzheimer’s and Parkinson’s disease, synaptic loss and mitochondrial dysfunction precede widespread cell death. Exosomes containing BDNF and mitochondrial transfer RNA can support surviving neurons and slow the rate of synaptic pruning. Reza-Zaldivar et al. (2019, Frontiers in Cellular Neuroscience) reviewed the preclinical evidence showing that exosome-mediated delivery of neurotrophins improved synaptic density in neurodegeneration models.
Chronic Neuroinflammation
Sustained microglial activation drives chronic neuroinflammation in conditions ranging from autoimmune encephalitis to post-concussive syndrome. MSC-derived exosomes carry IL-10 and transforming growth factor beta, both of which shift microglial phenotype from pro-inflammatory (M1) toward anti-inflammatory (M2). This phenotypic switch has been documented in multiple preclinical studies, including Li et al. (2019, Stem Cell Research & Therapy, n=36).
Cognitive Optimization
Even without overt disease, age-related decline in synaptic plasticity and neurovascular coupling reduces processing speed, working memory, and executive function. Exosomes containing BDNF and VEGF support angiogenesis and long-term potentiation, the cellular mechanism underlying learning and memory. Patients pursuing peak cognitive performance as part of our brain health protocol may receive exosome therapy to support these pathways alongside NAD+ and other interventions.
Brain Repair After Substance Use
Prolonged substance use causes measurable changes to prefrontal cortex function, dopaminergic signaling, and white matter integrity. Exosome therapy may support neural repair in the prefrontal and limbic circuits affected by that exposure, alongside neurocoaching with Dr. Drew Edwards and the patient’s other care.
How Exosome Therapy Fits Into Our Protocol
Dr. Orr does not administer exosome therapy as a standalone treatment. Every patient at The Neurogenesis Project begins with a full diagnostic workup: advanced neuroimaging, inflammatory biomarker panels, neurocognitive testing, and metabolic assessment. These results determine whether exosome therapy is appropriate and, if so, how it should be combined with other interventions.
For most patients, exosome therapy is one component within the Intensive Brain Health Program, a multi-day protocol that also includes NAD+ infusions, neuromodulation, nutritional optimization, and targeted supplementation. In cases where cellular repair is a primary goal, exosome therapy may be paired with mesenchymal stem cell administration as part of the Cellular Rejuvenation Program.
The decision to include exosomes depends on what the diagnostics show. If inflammatory markers are elevated, if imaging reveals white matter changes consistent with prior injury, or if neurocognitive testing identifies specific deficits in domains that respond to neurotrophic support, exosome therapy becomes part of the treatment plan. If the data does not support it, Dr. Orr will not recommend it.
Follow-up testing after treatment tracks objective changes in biomarkers, imaging, and cognitive performance. This allows Dr. Orr to measure the effect of each intervention and adjust the protocol over time.
Exosomes vs. Stem Cells
Stem cells and exosomes are related but distinct therapies. Mesenchymal stem cells are living cells that can differentiate into multiple tissue types, secrete growth factors, and modulate the immune system over an extended period after administration. Exosomes are the signaling vesicles that these cells release. They carry the molecular instructions but are not cells themselves. They do not replicate, and they do not engraft into tissue.
The practical difference matters for treatment planning. Stem cells persist in the body and continue to produce exosomes and other factors for days to weeks after administration. Exosomes act more quickly but have a shorter duration of effect. In some cases, Dr. Orr administers both: stem cells for sustained regenerative support and exosomes for an immediate burst of targeted signaling at the time of treatment.
There are also regulatory differences. Stem cell products fall under different FDA oversight categories depending on how they are processed. Exosome products, as acellular derivatives, are regulated as HCT/Ps under 21 CFR Part 1271 when minimally manipulated and used homologously.
For a full discussion of our stem cell protocols, see Stem Cell Therapy for Neurological Conditions.
Related Treatments
Stem Cell Therapy
Mesenchymal stem cells for sustained neural repair and immunomodulation. Often combined with exosome therapy in the Cellular Rejuvenation Program.
NAD+ IV Therapy
Intravenous NAD+ restores cellular energy metabolism and supports DNA repair. A core component of most treatment protocols at The Neurogenesis Project.
Cellular Rejuvenation Program
Our most intensive regenerative protocol, combining stem cells, exosomes, NAD+, and neuromodulation into a multi-day program tailored to each patient’s diagnostics.
What to Expect
Clinical evaluation and treatment candidacy
Estimated time: 30 minutes
Dr. Orr reviews your neurological history, current imaging, and laboratory results to determine whether exosome therapy is appropriate. Exosomes are typically recommended for patients with neuroinflammation, post-concussion syndrome, or neurodegenerative conditions where targeted signaling support may benefit neural repair.
Protocol design and informed consent
Estimated time: 20 minutes
Dr. Orr explains what exosomes are, how they differ from stem cells, and what the current clinical evidence supports for your condition. He outlines the dosing, administration route, and realistic timeline for expected effects. You review and sign informed consent.
Exosome preparation
Estimated time: 15 minutes
Cell-derived exosome preparations from a qualified source are verified for particle count and quality. The preparation is drawn and readied for IV administration in a sterile clinical setting.
Intravenous exosome administration
Estimated time: 45 minutes
Exosomes are delivered through a peripheral IV line over approximately 30 to 45 minutes. Because exosomes are cell-free vesicles, the infusion is generally well tolerated. Vital signs are monitored throughout. Some patients receive exosomes alongside NAD+ or other IV therapies in the same session.
Post-treatment monitoring and follow-up schedule
Estimated time: 20 minutes
You are observed for 15 to 20 minutes after the infusion. Dr. Orr discusses what to expect over the following days and weeks, schedules follow-up assessments, and adjusts your broader treatment plan based on how the exosome therapy integrates with other interventions.
Frequently Asked Questions
What are exosomes?+
Exosomes are tiny packets of biological instructions that cells naturally release to communicate with other cells. In our clinic, we use exosomes derived from stem cells to deliver anti-inflammatory and repair signals to the brain.
Read the full answer
Exosomes are nanoscale vesicles, typically 30 to 150 nanometers in diameter, released by cells as part of normal intercellular communication. They carry proteins, lipids, messenger RNA, and microRNAs from their parent cell to recipient cells, where they influence gene expression and cellular behavior. In regenerative medicine, exosomes derived from mesenchymal stem cells are used because they retain many of the signaling properties of the parent cell without being cells themselves.
How are exosomes administered at The Neurogenesis Project?+
By IV infusion during a supervised session at our clinic. In some cases, intranasal delivery is used to reach the brain more directly. Dr. Orr chooses the route based on your specific condition.
Read the full answer
Exosomes are administered intravenously during a supervised infusion session at our clinic. The IV route allows the vesicles to enter systemic circulation and reach the central nervous system. Some protocols also use intranasal delivery to more directly access brain tissue via the olfactory pathway. Dr. Orr determines the route and dosing based on each patient’s diagnostic workup and treatment goals.
Who is a candidate for exosome therapy?+
Patients with brain injuries, long COVID brain symptoms, early cognitive decline, or chronic brain inflammation that has not responded to other treatments. Dr. Orr determines candidacy based on your full evaluation.
Read the full answer
Candidates typically include individuals recovering from traumatic brain injury, those with persistent post-COVID neurological symptoms, patients in early stages of neurodegenerative conditions, and people experiencing chronic neuroinflammation that has not responded adequately to standard treatments. Dr. Orr evaluates candidacy through a full neurological assessment, advanced imaging, and laboratory workup before recommending exosome therapy.
How is exosome therapy different from stem cell therapy?+
Stem cell therapy delivers living cells. Exosome therapy delivers the repair and anti-inflammatory signals those cells produce, without the cells themselves. The two are sometimes combined.
Read the full answer
Stem cell therapy delivers living cells that can differentiate and integrate into tissue. Exosome therapy delivers the signaling molecules that stem cells produce, without the cells themselves. Exosomes do not replicate or engraft. They act as messengers, delivering instructions to existing cells to reduce inflammation, support repair, and modulate immune responses. The two therapies are sometimes used together, and Dr. Orr selects one or both based on the patient’s condition and goals.
What does exosome therapy cost?+
$1,800 per session, which covers the product, IV administration, and monitoring. Most patients receive exosome therapy as part of a broader treatment program.
Read the full answer
A single exosome therapy session at The Neurogenesis Project costs $1,800. This fee covers the exosome product, IV administration, and clinical monitoring during the infusion. Most patients receive exosome therapy as part of a broader treatment protocol, and total program costs depend on which additional therapies are included.
Is exosome therapy FDA-approved?+
No. Exosome therapy is not FDA-approved for any specific disease. We use products from FDA-registered tissue banks and discuss the regulatory status and evidence base with every patient before treatment.
Read the full answer
Exosome products used in clinical practice are regulated as human cells, tissues, and cellular and tissue-based products (HCT/Ps) under 21 CFR Part 1271. They are not FDA-approved drugs or biologics. The FDA has not approved exosome therapy for the treatment of any specific disease. At The Neurogenesis Project, we use exosome products from tissue banks that comply with FDA registration and current good tissue practice requirements, and we discuss the regulatory status and evidence base with every patient before treatment.
Where do the exosomes used at your clinic come from?+
From donated umbilical cord tissue collected from healthy donors after cesarean deliveries. The tissue is processed by FDA-registered laboratories, and every lot is tested for sterility, particle count, and quality before we use it.
Read the full answer
The exosomes we administer are derived from mesenchymal stem cells sourced from donated umbilical cord tissue. The tissue is collected from consenting, healthy donors following scheduled cesarean deliveries and screened for infectious diseases in accordance with FDA tissue banking requirements. We use only products from laboratories that provide certificates of analysis documenting particle count, size distribution, protein content, and sterility testing for each lot.
Has the FDA issued any warnings about exosome products?+
Yes. In 2019, the FDA warned about low-quality exosome products sold with unproven claims. We source only from FDA-registered labs that provide batch-specific quality testing for every lot we use.
Read the full answer
Yes. The FDA issued a public safety notification in 2019 warning about unapproved exosome products marketed with unsubstantiated claims. The warning addressed products not manufactured under appropriate quality controls. This is a legitimate concern. We source exclusively from laboratories that comply with FDA tissue banking regulations and provide batch-specific testing documentation. Exosome therapy is not FDA-approved for any specific disease indication. We administer it under the practice of medicine and discuss the evidence, including its limitations, with every patient.
What clinical evidence supports exosome therapy for neurological conditions?+
Animal studies show strong anti-inflammatory and repair effects. Human data so far comes from smaller studies showing safety and early positive signals. Large randomized trials are underway but not yet finished. We are upfront about where the evidence stands.
Read the full answer
The preclinical evidence is substantial. MSC-derived exosomes have demonstrated anti-inflammatory, immunomodulatory, and neurotrophic properties in animal models of TBI, stroke, spinal cord injury, and MS. Human clinical data consists primarily of case series and small open-label studies showing safety and preliminary efficacy signals. Randomized controlled trials in humans are underway but not yet completed. We present this evidence accurately and do not overstate what the current data supports.
Find Out Whether Exosome Therapy Is Right for You
Dr. Orr evaluates every patient individually. A consultation includes a full neurological assessment and diagnostic workup so that treatment recommendations are grounded in your specific clinical picture.